Choline 300 mg Timed Release

by Solaray · capsule · 100 capsules

  • On the market (NIH)
  • UPC 0 76280 04357 0
  • DSLD label 338749
  • Serving 1 capsule
  • 100 servings

Choline 300 mg Timed Release by Solaray lists one ingredient: 300 mg of choline per serving of 1 capsule. Its current label entered the NIH Dietary Supplement Label Database on September 25, 2025.

What is in Choline 300 mg Timed Release?

Each row as the label prints it, per serving of 1 capsule. The capsule beside an amount places it among every product in the NIH database that lists the same ingredient: the bar is the middle half of their amounts, the line in it the median, the whiskers the 10th and 90th percentiles; the green tick is the FDA Daily Value and the red dashed tick the adult upper limit (IOM).

Choline 300 mg Timed Release: Supplement Facts rows against the market (DSLD label 338749, January 2026 release)
IngredientAmount% DVAmong products listing it
Cholineas Choline Bitartrate300 mg55%*Choline in Choline 300 mg Timed Release against 4,738 products300 mg per serving; the middle half of products list 18 mg to 100 mg, the median 40 mg.DV 550 mgUL 3,500 mg300 mg

Higher than 92% of 4,738 products listing choline (median 40 mg). Per day at the most servings: 600 mg.

* % Daily Value computed from the printed amount and the FDA Daily Value (21 CFR 101.9); the label prints none for that row.

Source: NIH ODS Dietary Supplement Label Database, label 338749 (entered September 25, 2025), version 9.4.0. See the label on DSLD or its label image (PDF). Amounts are what the maker printed; DSLD does not test products. Daily Values: the FDA's Daily Value page.

Is that a lot?

The rows in the top or bottom tenth of the products that list the same ingredient, and any above the adult upper limit at the most servings a day the directions give:

  • Its 300 mg of choline is higher than 92% of the 4,738 choline products that print an amount; 376 list more.

The NIH database records 2 servings a day from the label's directions; its % Daily Values are for adults and children 4 or more years of age. The directions as printed are further down this page.

The Tolerable Upper Intake Level is the most of a nutrient per day, from food, water and supplements together, that is likely to pose no risk for almost all adults (Institute of Medicine, 2011). It does not apply under medical supervision. This page compares labels; it is not medical advice.

Sources: amounts from the DSLD label; Daily Values from 21 CFR 101.9(c)(8)(iv); adult upper limits from the Institute of Medicine's DRI summary tables (2011). How positions are computed.

Which products have the closest formulas?

6 products list the very same ingredients; the nearest amounts come first.

Source: ingredient lists of every product's current label in DSLD (version 9.4.0); similarity weights each shared ingredient by how rare it is.

What does the label say about taking it?

Quoted from the label as DSLD transcribed it: the maker's words, including any claim about what the product does, which the FDA has not evaluated and PlainVitamins does not endorse.

Directions
Directions: Use only as directed. Take 1 capsule twice daily or as needed.
Warnings
Warning: Do not use if safety seal is broken or missing. Keep your licensed health care practitioner informed when using this product.
Keep out of reach of children.
Storage
Store in a cool, dry place.

Source: label statements in DSLD label 338749.

What else is on the label?

Other ingredients: Gelatin, Stearic Acid, Silica, Magnesium Stearate.

Seals and symbols as the label prints them (the maker's; a certifier's own list confirms a seal): Lab Verified.

How many labels does Choline 300 mg Timed Release have?

One label is on file, entered on September 25, 2025.

  1. Label 338749 (current) Entered September 25, 2025 · on the market · 100 capsules · UPC 0 76280 04357 0

Source: DSLD label entry and market events, version 9.4.0 (labels entered through September 25, 2025).

Who makes it?

The label names Nutraceutical Corp. (manufacturer). All Solaray products.

Where next?